Abstract：
Aim: To investigate the efficacy and safety of bevacizumab in patients with recurrent low-grade serous ovarian carcinoma. Materials & methods: The data of patients who received at least two cycles of bevacizumab in combination with chemotherapy were retrospectively recorded. Results: The median age of 51 patients was 56 (range: 33-75) years. The complete response rate was 10.4% and the partial response rate was 43.7%. The objective response rate was 54.1%. Median progression-free survival was 15.9 months (95% CI: 9.1-22.6) and median overall survival was 42.5 months (95% CI: 37.2-47.8). Conclusion: Bevacizumab with chemotherapy is an effective option for treating recurrent ovarian low-grade serous carcinoma.
摘要：
目的:探讨贝伐单抗治疗复发性低级别浆液性卵巢癌的疗效和安全性。材料与方法：回顾性记录接受至少两个周期贝伐单抗联合化疗的患者数据。结果：51例患者的中位年龄为56岁（范围：33-75岁）。完全缓解率为10.4%，部分缓解率为43.7%。客观有效率为54.1%。中位无进展生存期为15.9个月（95%CI：9.1-22.6），中位总生存期为42.5个月（95%CI：37.2-47.8）。结论:贝伐单抗联合化疗是治疗复发性卵巢低级别浆液性癌的有效选择。
